Stock 6496 EXCELSIOR BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Excelsior Biopharma Inc.

Equities

6496

TW0006496003

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
27.95 TWD -0.36% Intraday chart for Excelsior Biopharma Inc. +0.72% -3.12%
Mar. 01 Excelsior Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Excelsior Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,897 1,666 1,384 1,363 1,298 1,356
Enterprise Value (EV) 1 1,146 1,402 606 625.1 542.7 1,121
P/E ratio 8.63 x 23.5 x 40.6 x -86 x -37.6 x -14.6 x
Yield 9.84% 2.8% 3.37% - - -
Capitalization / Revenue 1.12 x 1.08 x 0.96 x 1.02 x 1.93 x 1.76 x
EV / Revenue 0.68 x 0.91 x 0.42 x 0.47 x 0.81 x 1.45 x
EV / EBITDA 3.73 x 13.4 x 10.7 x 97.9 x -33.1 x -16.2 x
EV / FCF 18.5 x -7.18 x 1.2 x 9.96 x 122 x -8.03 x
FCF Yield 5.42% -13.9% 83.5% 10% 0.82% -12.4%
Price to Book 1.38 x 1.33 x 1.08 x 1.09 x 1.07 x 1.23 x
Nbr of stocks (in thousands) 46,667 46,667 46,667 46,606 46,689 47,014
Reference price 2 40.65 35.70 29.65 29.25 27.80 28.85
Announcement Date 4/1/19 2/12/20 2/8/21 2/16/22 2/18/23 3/1/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,689 1,540 1,444 1,338 671.8 771.6
EBITDA 1 307.5 104.3 56.82 6.386 -16.41 -69.31
EBIT 1 282.1 85.8 41.48 -8.767 -29.29 -81.13
Operating Margin 16.7% 5.57% 2.87% -0.66% -4.36% -10.51%
Earnings before Tax (EBT) 1 285.9 91.82 45.3 -10.03 -25.99 -81.95
Net income 1 221.8 71.01 35.3 -15.65 -33.76 -91.01
Net margin 13.13% 4.61% 2.45% -1.17% -5.03% -11.8%
EPS 2 4.710 1.520 0.7311 -0.3400 -0.7400 -1.982
Free Cash Flow 1 62.1 -195.2 505.8 62.74 4.434 -139.5
FCF margin 3.68% -12.67% 35.03% 4.69% 0.66% -18.08%
FCF Conversion (EBITDA) 20.19% - 890.21% 982.46% - -
FCF Conversion (Net income) 28% - 1,432.78% - - -
Dividend per Share 2 4.000 1.000 1.000 - - -
Announcement Date 4/1/19 2/12/20 2/8/21 2/16/22 2/18/23 3/1/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 751 264 778 738 755 236
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 62.1 -195 506 62.7 4.43 -140
ROE (net income / shareholders' equity) 16.4% 5.4% 2.78% -1.25% -2.77% -7.87%
ROA (Net income/ Total Assets) 10.6% 3.41% 1.53% -0.29% -1.03% -3.08%
Assets 1 2,091 2,081 2,314 5,341 3,277 2,955
Book Value Per Share 2 29.40 26.90 27.50 26.80 25.90 23.50
Cash Flow per Share 2 16.10 7.490 24.40 24.10 19.20 12.60
Capex 1 9.54 20.4 11.6 2.88 7.78 35.7
Capex / Sales 0.56% 1.32% 0.8% 0.21% 1.16% 4.62%
Announcement Date 4/1/19 2/12/20 2/8/21 2/16/22 2/18/23 3/1/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
EXCELSIOR BIOPHARMA INC. Stock Excelsior Biopharma Inc.
-3.12% 40.26M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6496 Stock
  4. Financials Excelsior Biopharma Inc.